公开(公告)号：EP4368177A1

公开(公告)日：2024-05-15

申请号：EP22853381.6

申请日：2022-08-01

申请人： Cellionbiomed Inc.

发明人： KIM, Seong-Jin ,  KIM, Seon-Myung

IPC分类号： A61K31/165 ,  A61P17/02 ,  A61P43/00

CPC分类号： A61P43/00 ,  A61P17/02 ,  A61K31/165

摘要： The present invention relates to a composition for treating hypertrophic scars and keloids, comprising a benzhydryl thioacetamide compound as an active ingredient. The benzhydryl thioacetamide compound inhibits cell proliferation and an increase in intracellular Ca2+ concentration, in fibroblasts, keratinocytes and vascular endothelial cells that are involved in skin fibrosis, and inhibits the synthesis of collagen, which is the extracellular matrix, and thus has the effect of effectively treating intractable hypertrophic scars and keloids.

公开(公告)号：EP4223291A1

公开(公告)日：2023-08-09

申请号：EP21852860.2

申请日：2021-07-29

申请人： Cellionbiomed Inc.

发明人： KIM, Seong-Jin ,  SUH, Suk-Hyo

IPC分类号： A61K31/325 ,  A61P43/00 ,  A61P1/16 ,  A61P11/00 ,  A61P37/00 ,  A61P35/00

摘要： The present invention relates to a composition for treating K Ca 3.1 channel-mediated diseases, comprising a phenylalkyl carbamate compound and, more specifically, to a pharmaceutical composition comprising, as an active ingredient, a phenylalkyl carbamate compound, the representative example of which is solriamfetol conventionally used as a therapeutic agent for narcolepsy, i.e., 2-amino-3-phenylpropyl carbamate, the pharmaceutical composition being able to be used for treating K Ca 3.1 channel-mediated diseases, for example, fibrotic diseases, autoimmune diseases, and cancer diseases, by inhibiting the activation of K Ca 3.1 channels in the cell membrane.

公开(公告)号：EP3851099A1

公开(公告)日：2021-07-21

申请号：EP19860298.9

申请日：2019-09-11

申请人： Cellionbiomed Inc.

发明人： SUH, Suk-Hyo ,  KIM, Seong-Jin

IPC分类号： A61K31/165 ,  A61K31/341 ,  A61P1/16 ,  A23L33/10 ,  A23K20/111 ,  A23K20/121

摘要： The present invention relates to a composition for treating fibrotic diseases, comprising a benzhydryl thioacetamide compound as an active ingredient, and more specifically to a composition for treating fibrotic diseases, which suppresses the expression of the channel protein K Ca 2.3 in a cell membrane and has excellent treatment effects particularly on hepatic fibrosis and pulmonary fibrosis.